| Antigen: |
CD21, Complement Receptor 2 (C3d receptor, EBV receptor) |
| Relevance: |
CD21 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CD21 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CD21 expression is also gradually lost after stimulation of B cells in vitro. CD21 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFNalpha. CD21 binds to CD23 and associates with CD19, CD81 and Leu13 to form a large signal-transduction complex involved in B cell activation. By inducing release of proinflammatory cytokines and upregulating expression of molecules involved in antigen presentation, CD21 modulates critical monocyte functions that may be relevant to allergic and inflammatory disorders |
| Clone: |
21A/5 |
| Subclass: |
IgG1 |
| Applications: |
Immunohistochemistry (frozen sections), FACS |
| Immunogen: |
CD21 |
| Reactivity: |
Human |
| Species raised in: |
Mouse |
| Fusion partner: |
NS-1 |
| Recommended growth conditions: |
RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| References: |
CD Guide for CD21 (1989) In Knapp W, et al (eds) Leucocyte Typing IV, Oxford University Press, Oxford, New York and Tokyo, p 1080 |
| Notes: |
Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Click here to view Notes and Disclaimer information |
